中東・アフリカ多発性硬化症治療薬市場規模・シェア・COVID-19影響分析薬剤分類別（免疫調節剤、免疫抑制剤、インターフェロン、その他）、投与経路別（経口・注射{筋肉内、皮下、静脈内}）、流通経路別（病院薬局、小売薬局、オンライン薬局）、および地域別予測、2023-2030年

最終更新: November 17, 2025 | フォーマット: PDF | 報告-ID: FBI107919

私たちはお客様の研究目標に合わせてレポートをカスタマイズし、競争上の優位性を獲得し、十分な情報に基づいた意思決定を行えるように支援します。

当社のコンサルティング能力を理解するために30分のセッションを予約してください。 – 今すぐ予約

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Multiple Sclerosis - For Key Countries
2. Patent Snapshot, Key Players
3. Pipeline Analysis & R&D Investments
4. Key Industry Developments (Mergers, Acquisitions, Partnerships; etc.)
5. Impact of COVID-19 on the Market
Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Immunosuppressants
  3. Interferons
  4. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Injection
    1. Intramuscular
    2. Subcutaneous
    3. Intravenous
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
4. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. South Africa
  2. GCC
  3. Rest of Middle East & Africa
Competitive Analysis
1. Middle East & Africa Market Share Analysis
2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  1. Biogen
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  2. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  3. Merck KGaA
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  5. Novartis AG
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  6. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  7. Pfizer Inc.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  9. Bristol-Myers Squibb Company
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Multiple Sclerosis - For Key Countries
2. Patent Snapshot, Key Players
3. Pipeline Analysis & R&D Investments
4. Key Industry Developments (Mergers, Acquisitions, Partnerships; etc.)
5. Impact of COVID-19 on the Market
Middle East & Africa Multiple Sclerosis Drugs Market Analysis, Insights and Forecast, 2019-2030
1. Market Analysis, Insights and Forecast – By Drug Class
  1. Immunomodulators
  2. Immunosuppressants
  3. Interferons
  4. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Oral
  2. Injection
    1. Intramuscular
    2. Subcutaneous
    3. Intravenous
3. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
4. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. South Africa
  2. GCC
  3. Rest of Middle East & Africa
Competitive Analysis
1. Middle East & Africa Market Share Analysis
2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  1. Biogen
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  2. Teva Pharmaceutical Industries Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  3. Merck KGaA
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  4. Sanofi
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  5. Novartis AG
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  6. F. Hoffmann-La Roche Ltd.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  7. Pfizer Inc.
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  8. Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation)
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)
  9. Bristol-Myers Squibb Company
    1. Overview,
    2. Products,
    3. SWOT Analysis,
    4. Recent Developments,
    5. Strategies,
    6. Financials (Based on Availability)

フィギュア一覧

Figure 1: Middle East & Africa Multiple Sclerosis Drugs Market Revenue Breakdown (USD Billion, %) by Country/Sub-region, 2022 & 2030

Figure 2: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Drug Class, 2022 & 2030

Figure 3: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Route of Administration, 2022 & 2030

Figure 4: Middle East & Africa Multiple Sclerosis Drugs Market Value Share (%), by Distribution Channel, 2022 & 2030

Figure 5: Middle East & Africa Multiple Sclerosis Drugs Market Value (USD Billion), By Country/ Sub-region, 2022 & 2030

Figure 6: Middle East & Africa Multiple Sclerosis Drugs Market Share (%), By Company

テーブルのリスト

Table 1: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Drug Class, 2019–2030

Table 2: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Route of Administration, 2019–2030

Table 3: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Injection, 2019–2030

Table 4: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Distribution Channel, 2019–2030

Table 5: Middle East & Africa Multiple Sclerosis Drugs Market Revenue (USD Billion) Forecast, by Country/Sub-region, 2019–2030

勉強期間: 2019-2030
基準年: 2022
歴史的なデータ: 2019-2021
ページ数: 109

今すぐ購入

無料サンプルをダウンロード

セキュリティコード

成長アドバイザリーサービス

クライアント

目次

フィギュア一覧

テーブルのリスト